- RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE2, PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.
For: Metastatic Uveal MelanomaUnited States · Australia · Belgium - RecruitingPHASE3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
This study is looking at a new medicine called AL3818 (anlotinib) for people with advanced alveolar soft part sarcoma (ASPS). It aims to see how safe and effective it is. Currently, it's only for ASPS patients.
For: Alveolar Soft Part Sarcoma · Leiomyosarcoma · Synovial SarcomaUnited States · China · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
This study looks at a new treatment called pembrolizumab, combined with standard chemotherapy, for adults recently diagnosed with classical Hodgkin lymphoma. Researchers want to see how many patients go into complete remission at the end of the treatment plan.
For: Classical Hodgkin LymphomaFrance · Poland · Spain - AuthorisedTherapeutic confirmatory (Phase III)
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
This study looks at treating a children's cancer called neuroblastoma. We want to find the best way to treat children who have a lower chance of a severe form of the disease. This will help doctors choose the right treatment to give children the best chance of getting better.
For: low and intermediate risk neuroblastomaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
This study compares two common treatments for advanced Hodgkin lymphoma (a type of cancer). It looks at how well they work, their side effects, and their impact on quality of life, especially for older patients.
For: Advanced Stage of Hodgkin LymphomaNorway · Austria · Netherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
This study looks at a new treatment called IMCgp100 for advanced eye melanoma that has not been treated before. It compares this new drug to standard treatments to see which works best and is safest for patients.
For: Previously untreated advanced uveal melanoma (UM)Spain · Italy · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockade (PROMIT: PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy)
This study looks at a new way to treat melanoma, a type of skin cancer, using existing drugs. It combines an older chemotherapy drug (dacarbazine) with newer immunotherapy treatments (pembrolizumab, nivolumab, ipilimumab) for people whose cancer hasn't responded to immunotherapy alone. We want to see if this combination helps more people.
For: MelanomaGermany - RecruitingPHASE3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This study compares a new treatment called IMA203 with standard care for advanced skin melanoma that has already been treated. Its main goal is to see if IMA203 is more effective and safe for patients who have limited treatment options.
For: Melanoma, Cutaneous MalignantUnited States · Canada · France - Active not recruitingPHASE3
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
This study is looking at a new combination of medicines, naporafenib and trametinib, for people with a specific type of advanced melanoma. It aims to see if this combination works better than standard treatments for patients whose melanoma has certain genetic changes and has progressed after other treatments.
For: Advanced or Metastatic NRAS-mutant MelanomaUnited States · Australia · Canada - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
For: Hodgkin LymphomaUnited States · Brazil · Colombia